Professor Paul Loadman,Professor
Information about Professor Paul Loadman at the University of Bradford.
- Institute of Cancer Therapeutics
(Faculty of Life Sciences) - Email:
- p.m.loadman@bradford.ac.uk
- Telephone:
- +44 1274 233228
Biography
Pharmacokinetics and tumour drug metabolism of anti-cancer drugs Professor Paul Loadman heads the drug metabolism team at the Institute of Cancer Therapeutics, University of Bradford and has >20years experience studying the pharmacokinetics and metabolism of anti-cancer drugs. The team in Bradford have studied a wide range of clinically available and novel small molecules including antimetabolites, platinating and alkylating agents, peptides and antivascular compounds. Prof Loadman is actively involved in the design, analysis and reporting of pre-clinical and clinical pharmacokinetic studies and acts as a pharmacokinetic and drug metabolism consultant for numerous pharmaceutical and biotechnology companies. Together with Prof Twelves (Clinical Director,) the DMPK team have established a Quality Management System within the ICT which has enabled a strong involvement in the pharmacokinetic monitoring of small molecules in major clinical trials. Other major clinical collaborations include with Professor Mark Hull at the University of Leeds (The seAFOod Polyp Prevention Trial, www.seafood-trial.co.uk) where the laboratory in Bradford are analyzing a series of bioactive lipid mediators such as ω-3 PUFAs, resolvin E1 and PGE-M in plasma, urine, erythrocytes and rectal mucosa in order to gain insights into the mechanism of action of EPA and aspirin.
Research
Pharmacokinetics and tumour drug metabolism of anti cancer drugs Matrix metalloproteinases as targets for tumour-selective delivery of anticancer therapeutics Drug delivery and prodrug design Novel advances in analytical techniques. HPLC, GC, CE and LC/MS/MS Drug interactions both in vitro and in vivo
Professional activities
Information about education, employment and areas of particular interest for Professor Paul Loadman is as follows:
- Royal Society of Biology , Royal Society of Biology
- Drug Metabolism Discussion Group (DMDG), Drug Metabolism Discussion Group (DMDG)
- Pharmacokinetics and Molecular Mechanisms (PAMM) Group, Pharmacokinetics and Molecular Mechanisms (PAMM) Group
- European Association for Cancer Research , European Association for Cancer Research
- American Association for Cancer Research , American Association for Cancer Research
- British Association for Cancer Research , British Association for Cancer Research
Education
- University of Bradford - PhD
Publications
There are 118 publications involving or that are attributed to Professor Paul Loadman. They are listed as:
- peer reviewed journal (111)
- reviews (7)
Peer Reviewed Journal
| Title | Year | Publication name | Journal | Volume | Pages | Authors | Editors | ISSN | Publisher | DOI | Location |
|---|---|---|---|---|---|---|---|---|---|---|---|
| APOE genotype, eicosapentaenoic acid (EPA) supplementation and n-3 highly unsaturated fatty acid (HUFA) levels in patients with multiple colorectal polyps | 2024 | Prostaglandins Leukotrienes and Essential Fatty Acids | 201 | Ge SunJohn, R Davies ,Tracey Mell, Mark Harland, Rasha M H Saleh, Amanda D Race, Paul M Loadman, Elizabeth A Williams, Anne Marie Minihane, Mark A Hull | doi: 10.1016/j.plefa.2024.102623 | ||||||
| Plasma and rectal mucosal oxylipin levels during aspirin and eicosapentaenoic acid treatment in the seAFOod polyp prevention trial. | 2023 | Prostaglandins Leukotrienes and Essential Fatty Acids | 192 | Fuller H;Race AD;Fenton H;Burke L;Downing A;Williams EA;Rees CJ;Brown LC;Loadman PM;Hull MA; | 1532-2823 | 10.1016/j.plefa.2023.102570 | |||||
| Polymorphisms in Cyclooxygenase, Lipoxygenase and TP53 genes predict colorectal polyp risk reduction by aspirin in the seAFOod polyp prevention tria | 2023 | Cancer Prevention Research | september | John R Davies, Tracey Mell, Harriett Fuller, Mark Harland, Rasha N M Saleh, Amanda D Race, Colin J Rees, Louise C Brown, Paul M Loadman, Amy Downing, Anne Marie Minihane, Elizabeth A Williams Mark A Hull | 1940-6215 | AACR | https://doi.org/10.1158/1940-6207.CAPR-23-0111 | ||||
| Randomised, placebo-controlled, phase 3 trial of the effect of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases: EPA for Metastasis Trial 2 (EMT2) study protocol | 2023 | BMJ Open | 13 | Mark A Hull , Pei Loo Ow, Sharon Ruddock, Tim Brend, Alexandra F Smith, Helen Marshall, Mingyang Song, Andrew T Chan, Wendy S Garrett, Omer Yilmaz, David A Drew, Fiona Collinson, Andrew J Cockbain, Robert Jones, Paul M Loadman , Peter S Hall, Catherine Moriarty, David A Cairns, Giles J Toogood | BMJ | doi:10.1136/bmjopen-2023-077427 | |||||
| Colorectal polyp outcomes after participation in the seAFOod polyp prevention trial: Evidence of rebound elevated colorectal polyp risk after short-term aspirin use. | 2023 | Alimentary Pharmacology and Therapeutics | Downing A;Fenton H;Nickerson C;Loadman PM;Williams EA;Rees CJ;Brown LC;Morris EJA;Hull MA; | 1365-2036 | 10.1111/apt.17646 | ||||||
| Cancer-specific glycosylation of CD13 impacts its detection and activity in preclinical cancer tissues. | 2023 | Iscience | 26 | Barnieh FM;Galuska SP;Loadman PM;Ward S;Falconer RA;El-Khamisy SF; | 2589-0042 | 10.1016/j.isci.2023.108219 | |||||
| Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs. | 2022 | Nature | 605 | Eschweiler S;Ramírez-Suástegui C;Li Y;King E;Chudley L;Thomas J;Wood O;von Witzleben A;Jeffrey D;McCann K;Simon H;Mondal M;Wang A;Dicker M;Lopez-Guadamillas E;Chou TF;Dobbs NA;Essame L;Acton G;Kelly F;Halbert G;Sacco JJ;Schache AG;Shaw R;McCaul JA;Paterson C;Davies JH;Brennan PA;Singh RP;Loadman PM;Wilson W;Hackshaw A;Seumois G;Okkenhaug K;Thomas GJ;Jones TM;Ay F;Friberg G;Kronenberg M;Vanhaesebroeck B;Vijayanand P;Ottensmeier CH; | 1476-4687 | 10.1038/s41586-022-04685-2 | |||||
| Implementing subtype-specific pre-clinical models of breast cancer to study pre-treatment aspirin effects | 2022 | Cancer Medicine | 11 | Ian S. Miller, Sonja Khan, Liam P. Shiels, Sudipto Das, Alice C. O' Farrell, Kate Connor, Adam Lafferty, Bruce Moran, Claudio Isella, Paul Loadman, Emer Conroy, Susan Cohrs, Roger Schibli, Robert S. Kerbel, William M. Gallagher, Elisabetta Marangoni, Kathleen Bennett, Darran P. O' Connor, Róisín M. Dwyer, Annette T. Byrne | https://doi.org/10.1002/cam4.4756 | ||||||
| Targeted delivery of a colchicine analogue provides synergy with ATR inhibition in cancer cells | 2022 | Biochemical Pharmacology | 10.1016/j.bcp.2022.115095 | ||||||||
| The role of MT1-MMP in the progression and metastasis of osteosarcoma | 2022 | Journal of Cancer Metastasis and Treatment | 9 | Spencer, H.L.M.; Shnyder, S.D.; Loadman, P.M.; Falconer, R.A. | DOI:10.20517/2394-4722.2021.174 | ||||||
| A Single Short 'Tone Burst' Results in Optimal Drug Delivery to Tumours Using Ultrasound-Triggered Therapeutic Microbubbles. | 2022 | Pharmaceutics | 14 | Ingram N;McVeigh LE;Abou-Saleh RH;Batchelor DVB;Loadman PM;McLaughlan JR;Markham AF;Evans SD;Coletta PL; | 1999-4923 | 10.3390/pharmaceutics14030622 | |||||
| How can the potential of the duocarmycins be unlocked for cancer therapy? | 2021 | Drug Discovery Today | 26 | Jukes Z;Morais GR;Loadman PM;Pors K; | 1878-5832 | 10.1016/j.drudis.2020.11.020 | |||||
| Targeted microbubbles carrying lipid-oil-nanodroplets for ultrasound-triggered delivery of the hydrophobic drug, Combretastatin A4. | 2021 | Nanomedicine: Nanotechnology, Biology, and Medicine | Charalambous A;Mico V;McVeigh LE;Marston G;Ingram N;Volpato M;Peyman SA;McLaughlan JR;Wierzbicki A;Loadman P;Bushby RJ;Markham AF;Evans SD;Coletta PL; | 1549-9642 | 10.1016/j.nano.2021.102401 | ||||||
| An assay for quantitative analysis of polysialic acid expression in cancer cells | 2021 | Carbohydrate Polymers | 259 | Guo, X.; Elkashef, S.M.; Patel, A.; Ribeiro Morais, G.; Shnyder S.D.; Loadman, P.M.; Patterson, L.H.; Falconer, R.A. | 10.1016/j.carbpol.2021.117741 | ||||||
| Progress towards a clinically-successful ATR inhibitor for cancer therapy | 2021 | Current Research in Pharmacology and Drug Discovery | 2 | 100017 | Barnieh, F.M.; Loadman, P.M.; Falconer, R.A. | 10.1016/j.crphar.2021.100017 | |||||
| Luminal bioavailability in the distal small intestine and changes to the ileal microbiome after oral administration of omega-3 polyunsaturated fatty acids | 2021 | Journal of Nutrition | may24 | Gael Nana, Henry Watson, Suparna Mitra, Caroline Young, Henry M Wood, Sarah L Perry, Amanda D Race, Philip Quirke, Giles J Toogood, Paul M Loadman, Mark A Hull | doi: 10.1093/jn/nxab113 | ||||||
| Is tumour-expressed aminopeptidase N (APN/CD13) structurally and functionally unique? | 2021 | Biochimica et Biophysica Acta - Reviews on Cancer | 1876 | Barnieh FM;Loadman PM;Falconer RA; | 1879-2561 | 10.1016/j.bbcan.2021.188641 | |||||
| Cytochrome P450 Binding and Bioactivation of Tumor-targeted Duocarmycin Agents. | 2021 | Drug Metabolism And Disposition: The Biological Fate Of Chemicals | Bart AG;Morais G;Vangala VR;Loadman PM;Pors K;Scott EE; | 1521-009X | 10.1124/dmd.121.000642 | ||||||
| Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compounds. | 2021 | Bioorganic and Medicinal Chemistry | 40 | Ortuzar N;Karu K;Presa D;Morais GR;Sheldrake HM;Shnyder SD;Barnieh FM;Loadman PM;Patterson LH;Pors K;Searcey M; | 1464-3391 | 10.1016/j.bmc.2021.116167 | |||||
| Cytochrome P450 isoforms 1A1, 1B1 AND 2W1 as targets for therapeutic intervention in head and neck cancer. | 2021 | Scientific Reports | 11 | Presa D;Khurram SA;Zubir AZA;Smarakan S;Cooper PA;Morais GR;Sadiq M;Sutherland M;Loadman PM;McCaul J;Shnyder SD;Patterson LH;Pors K; | 2045-2322 | 10.1038/s41598-021-98217-z | |||||
| Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compounds | 2021 | BIOORGANIC & MEDICINAL CHEMISTRY | 40 | Natalia Ortuzar, Kersti Karu, Daniela Presa, Goreti R. Morais, Helen M. Sheldrake, Steve D. Shnyder, Francis M. Barnieh, Paul M. Loadman, Laurence H. Patterson, Klaus Pors, Mark Searcey | 10.1016/j.bmc.2021.116167 | ||||||
| An efficient assay for identification and quantitative evaluation of potential polysialyltransferase inhibitors. | 2020 | ANALYST (PRINT) | 145 | 4512 - 4521 | Guo X; Malcolm J.R.; Ali M.M.; Ribeiro Morais G; Shnyder S.D.; Loadman P.M.; Patterson L.H.; Falconer R.A. | 1364-5528 | 10.1039/d0an00721h | ||||
| Ultrasound-triggered therapeutic microbubbles enhance the efficacy of cytotoxic drugs by increasing circulation and tumour drug accumulation and limiting bioavailability and toxicity in normal tissues | 2020 | Theranostics | 10 | Nicola Ingram1*, Laura E. McVeigh1*, Radwa H. Abou-Saleh2,3, Juliana Maynard4, Sally A. Peyman2, James R. McLaughlan5, Michael Fairclough6, Gemma Marston1, Elizabeth M.A. Valleley 1, Jorge L. Jimenez-Macias1, Antonia Charalambous1, William Townley4, Malcolm Haddrick4, Antonia Wierzbicki7, Alexander Wright1, Milène Volpato1, Peter B. Simpson4, Darren E. Treanor1, Neil H. Thomson8, Paul M. Loadman7, Richard J. Bushby2,9, Benjamin R.G. Johnson2, Pamela F. Jones1, Tony Evans1, Steven Freear5, Alexander F. Markham1, Stephen D. Evans2,*, P. Louise Coletta1,* | ISSN: 1838-7640 | Ivy Spring | DOI: 10.7150/thno.49670 | ||||
| Inactivation of apaziquone by haematuria: implications for the design of phase III clinical trials against non-muscle invasive bladder cancer | 2019 | Cancer Chemotherapy and Pharmacology | 83 | Roger M. Phillips, Paul M. Loadman, Guru Reddy | 10.1007/s00280-019-03812-7 | ||||||
| Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance | 2019 | Critical Reviews in Oncology/Hematology | 141 | 153 - 162 | Jove, M.; Spencer, Jade A.; Clench, M.; Loadman, Paul M.; Twelves, C. | DOI.org/10.1016/j.critrevonc.2019.06.008 | |||||
| Theranostic nanoparticles enhance the response of glioblastomas to radiation | 2019 | Nanotheranostics | 3 | 299 - 310 | Wu, W.; Klockow, J.L.; Mohanty, S.; Ku, K.S.; Aghighi, M.; Melemenidis, S.; Chen, Z.; Li, K.; Ribeiro Morais, Goreti; Zhao, N.; Schlegel, J.; Graves, E.E.; Rao, J.; Loadman, Paul M.; Falconer, R.A.; Mukherjee, S.; Chin, F.T.; Daldrup-Link, H.E. | 10.7150/ntno.35342 | |||||
| Recent advances in the analysis of polysialic acid from complex biological systems | 2019 | Carbohydrate Polymers | 16 | Xiaoxiao Guo, Sara M. Elkashef, Mark Sutherland, Paul M. Loadman and Robert A. Falconer | 10.1016/j.carbpol.2019.115145 | ||||||
| Cellular uptake and efflux of palbociclib in vitro in single cell and spheroid models. | 2019 | Journal of Pharmacology and Experimental Therapeutics | 371 | Jove M;Spencer JA;Hubbard ME;Holden EC;O'Dea RD;Brook BS;Phillips RM;Smye SW;Loadman P;Twelves CJ; | 1521-0103 | 10.1124/jpet.119.256693 | |||||
| A study of inter-individual variability in the Phase II metabolism of xenobiotics in human skin | 2018 | Toxicology Letters | 292 | 63 - 72 | Spriggs, S.; Cubberley, R.; Loadman, Paul M.; Sheffield, D.; Wierzbicki, Antonia | doi.org/10.1016/j.toxlet.2018.04.011 | |||||
| Structural properties governing drug-plasma protein binding determined by high-performance liquid chromatography method | 2018 | Journal of Pharmaceutical and Biomedical Analysis | 149 | 16 - 21 | Kamble, Sharad R.; Loadman, Paul M.; Abraham, M.H.; Liu, Xiangli | doi.org/10.1016/j.jpba.2017.10.022 | |||||
| Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial | 2018 | Lancet | 392 | 2583 - 2594 | Hull, M.A.; Sprange, K.; Hepburn, T.; Tan, W.; Shafayat, A.; Rees, C.J.; Clifford, G.; Logan, R.F.; Loadman, Paul M.; Williams, E.A.; Whitham, D.; Montgomery, A.A. | doi.org/10.1016/S0140-6736(18)31775-6 | |||||
| A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota | 2018 | Gut | 67 | 1974 - 1983 | Watson, H.; Mitra, S.; Croden, F.C.; Taylor, M.; Wood, H.M.; Perry, S.L.; Spencer, Jade A.; Quirke, P.; Toogood, G.J.; Lawton, C.L.; Dye, L.; Loadman, Paul M.; Hull, M.A. | doi: 10.1136/gutjnl-2017-314968 | |||||
| Rationalized Computer-Aided Design of Matrix-Metalloprotease-Selective Prodrugs | 2017 | Journal of Medicinal Chemistry | 60 | 4496 - 4502 | Jain, M.; Harburn, J.J.; Gill, J.H.; Loadman, P.M.; Falconer, R.A.; Mooney, C.A.; Cobb, S.L.; Berry, David J. | 10.1021/acs.jmedchem.6b01472 | |||||
| Membrane-type matrix metalloproteinases: expression, roles in metastatic prostate cancer progression and opportunities for drug targeting | 2017 | Journal of Cancer Metastasis and Treatment | 3 | 315 - 327 | Falconer, R.A.; Loadman, P.M. | 10.20517/2394-4722.2017.40 | |||||
| Drug delivery in a tumour cord model: a computational simulation | 2017 | Royal Society Open Science | 4 | 170014 | Hubbard, M.E.; Jove, M.; Loadman, Paul M.; Phillips, Roger M.; Twelves, Christopher J.; Smye, S.W. | doi.org/10.1098/rsos.170014 | |||||
| A liquid chromatography-tandem mass spectrometry method to measure fatty acids in biological samples | 2017 | J Chromatography B | 1055 | 125 - 134 | Volpato, Milène; Spencer, Jade A.; Race, Amanda D.; Munarini, A.; Belluzzi, A.; Cockbain, A.; Hull, M.; Loadman, Paul M. | doi.org/10.1016/j.jchromb.2017.04.030 | |||||
| A novel theranostic strategy for MMP-14 expressing glioblastomas impacts survival | 2017 | Molecular Cancer Therapeutics | 16 | 1909 - 1921 | Mohanty, S.; Chen, Z.; Li, K.; Ribeiro Morais, G.; Klockow, J.; Yerneni, K.; Pasani, L.; Chin, F.T.; Mitra, S.; Cheshier, S.; Chang, E.; Gambhir, S.S.; Rao, J.; Loadman, P.M.; Falconer, R.A.; Daldrup-Link, H.E. | 10.1158/1535-7163.MCT-17-0022 | |||||
| Proteases in cancer drug delivery | 2016 | Advanced Drug Delivery Reviews | 97 | 144 - 145 | Vandooren, J.; Opdenakker, G.; Loadman, Paul M.; Edwards, D.R. | dx.doi.org/10.1016/j.addr.2015.12.020 | |||||
| Measurement of red blood cell eicosapentaenoic acid (EPA) levels in a randomised trial of EPA in patients with colorectal cancer liver metastases | 2016 | Prostaglandins Leukotrienes and Essential Fatty Acids | 115 | Watson, H.; Cockbain, A.J.; Spencer, Jade A.; Race, Amanda D.; Volpato, Milène; Loadman, Paul M.; Toogood, G.J.; Hull, M.A. | dx.doi.org/10.1016/j.plefa.2016.10.003 | ||||||
| An optimised assay for quantitative, high-throughput analysis of polysialyltransferase activity | 2016 | ANALYST (PRINT) | 141 | 5849 - 5856 | Elkashef, Sara M.; Sutherland, Mark H.; Patterson, Laurence H.; Loadman, Paul M.; Falconer, Robert A. | 10.1039/c6an01073c | |||||
| Polysialic acid sustains cancer cell survival and migratory capacity in a hypoxic environment | 2016 | Scientific Reports | 6 | 33026 | Elkashef, Sara M.; Allison, Simon J.; Sadiq, Maria; Basheer, Haneen A.; Ribeiro Morais, Goreti; Loadman, Paul M.; Pors, Klaus; Falconer, Robert A. | 10.1038/srep33026 | |||||
| Probing cytochrome P450-mediated activation with a truncated azinomycin analogue | 2015 | MedChemComm | 6 | 187 - 191 | Vinader, Victoria; Sadiq, Maria; Sutherland, Mark H.; Huang, M.Y.; Loadman, Paul M.; Elsalem, Lina M.I.; Shnyder, Steven D.; Cui, H.J.; Afarinkia, Kamyar; Searcey, M.; Patterson, Laurence H.; Pors, Klaus | dx.doi.org/10.1039/c4md00411f | |||||
| Thin-layer chromatography/matrix-assisted laser desorption/ionisation mass spectrometry and matrix-assisted laser desorption/ionisation mass spectrometry imaging for the analysis of phospholipids in LS174T colorectal adenocarcinoma xenografts treated with the vascular disrupting agent DMXAA | 2015 | Rapid Communications In Mass Spectrometry | 29 | 1288 - 1296 | Batubara, A.; Carolan, V.A.; Loadman, Paul M.; Sutton, Chris W.; Shnyder, Steven D.; Clench, M.R. | doi.org/10.1002/rcm.7223 | |||||
| Eicosapentaenoic acid free fatty acid prevents and suppresses colonic neoplasia in colitis-associated colorectal cancer acting on Notch signaling and gut microbiota | 2014 | International Journal of Cancer | 135 | 204 - 213 | Piazzi, G.; D'Argenio, G.; Prossomariti, A.; Lembo, V.; Mazzone, G.; Candela, M.; Biagi, E.; Brigidi, P.; Vitaglione, P.; Fogliano, V.; D'Angelo, L.; Fazio, C.; Munarini, A.; Belluzzi, A.; Ceccarelli, C.; Chieco, P.; Balbi, T.; Loadman, Paul M.; Hull, M.A.; Romano, M.; Bazzoli, F.; Ricciardiello, L. | doi.org/10.1002/ijc.28853 | |||||
| Development of Novel Tumor-Targeted Theranostic Nanoparticles Activated by Membrane-Type Matrix Metalloproteinases for Combined Cancer Magnetic Resonance Imaging and Therapy | 2014 | Small | 10 | 565 - 575 | Ansari, C.; Tikhomirov, G.A.; Hong, S.H.; Falconer, Robert A.; Loadman, Paul M.; Gill, Jason H.; Castaneda, R.; Hazard, F.K.; Tong, L.; Lenkov, O.D.; Felsher, D.W.; Rao, J.; Daldrup-Link, H.E. | 10.1002/smll.201301456 | |||||
| Tumor-Targeted Prodrug ICT2588 Demonstrates Therapeutic Activity Against Solid Tumors and Reduced Potential For Cardiovascular Toxicity | 2014 | Molecular Cancer Therapeutics | 11 | 1294 - 1300 | Gill, Jason H.; Loadman, Paul M.; Shnyder, Steven D.; Cooper, Patricia A.; Atkinson, Jennifer M.; Ribeiro Morais, Goreti; Patterson, Laurence H.; Falconer, Robert A. | 10.1021/mp400760b | |||||
| Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid | 2014 | Gut | 63 | 1760 - 1768 | Cockbain, A.J.; Volpato, Milène; Race, Amanda D.; Munarini, A.; Fazio, C.; Belluzzi, A.; Loadman, Paul M.; Toogood, G.J.; Hull, M.A. | doi.org/10.1136/gutjnl-2013-306445 | |||||
| Mathematical and computational models of drug transport in tumours | 2014 | Journal of the Royal Society Interface | 11 | 94 | Groh, C.M.; Hubbard, M.E.; Jones, P.F.; Loadman, Paul M.; Periasamy, Nagarajan; Sleeman, B.D.; Smye, S.W.; Twelves, Christopher J.; Phillips, Roger M. | doi.org/10.1098/rsif.2013.1173 | |||||
| Mucosal biomarkers of colorectal cancer risk do not increase at 6 months following sleeve gastrectomy, unlike gastric bypass | 2014 | Bmc Obesity | 22 | 202 - 210 | Kant, P.; Perry, S.L.; Dexter, S.P.; Race, Amanda D.; Loadman, Paul M. | doi.org/10.1002/oby.20493 | |||||
| In vitro 3D colon tumor penetrability of SRJ09, a new anti-cancer andrographolide analog | 2014 | Investigational New Drugs | 32 | 806 - 814 | Wong, C.C.; Periasamy, Nagarajan; Sagineedu, S.R.; Sidik, S.; Sumon, S.H.; Loadman, Paul M.; Phillips, Roger M.; Lajis, N.H.; Stanslas, J. | doi.org/10.1007/s10637-014-0105-6 | |||||
| Targeting of Hypoxia in AQ4N-treated Tumour Xenografts by MALDI-Ion Mobility Separation-Mass Spectrometry Imaging | 2013 | Djidja, M-C.; Francese, S.; Claude, E.; Loadman, Paul M.; Sutton, Chris W.; Shnyder, Steven D.; Cooper, Patricia A.; Patterson, Laurence H.; Carolan, V.A.; Clench, M.R. | |||||||||
| Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins | 2013 | Travica, S.; Pors, Klaus; Loadman, Paul M.; Shnyder, Steven D.; Johansson, I.; Alandas, Mohammed N.; Sheldrake, Helen M.; Mkrtchian, S.; Patterson, Laurence H.; Ingelman-Sundberg, M. | |||||||||
| Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder | 2013 | Sutherland, Mark H.; Gill, Jason H.; Loadman, Paul M.; Laye, Jonathan P.; Sheldrake, Helen M.; Illingworth, Nicola A.; Alandas, Mohammed N.; Cooper, Patricia A.; Searcey, M.; Pors, Klaus; Shnyder, Steven D.; Patterson, Laurence H. | |||||||||
| Re-engineering of the Duocarmycin Structural Architecture Enables Bioprecursor Development Targeting CYP1A1 and CYP2W1 for Biological Activity | 2013 | Sheldrake, Helen M.; Travica, S.; Johansson, I.; Loadman, Paul M.; Sutherland, Mark H.; Elsalem, Lina M.I.; Illingworth, Nicola A.; Cresswell, Alexander J.; Reuillon, Tristan; Shnyder, Steven D.; Mkrtchian, S.; Searcey, M.; Ingelman-Sundberg, M.; Patterson, Laurence H.; Pors, Klaus | |||||||||
| A randomised controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma (or polyp) prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme: The seAFOod (Systematic Evaluation of Aspirin and Fish Oil) Polyp Prevention Trial | 2013 | Hull, M.A.; Sandell, A.C.; Montgomery, A.A.; Logan, R.F.A.; Clifford, G.M.; Rees, C.J.; Loadman, Paul M.; Whitham, D. | |||||||||
| A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): Study protocol for a randomized controlled trial | 2013 | Trials | 14 | Hull M.;Sandell A.;Montgomery A.;Logan R.;Clifford G.;Rees C.;Loadman P.;Whitham D. | 1745-6215 | 10.1186/1745-6215-14-237 | |||||
| Identification of Stage-Specific Breast Markers using Quantitative Proteomics | 2013 | Shaheed, Sadr-ul; Rustogi, Nitin; Scally, Andy J.; Wilson, J.; Thygesen, H.; Loizidou, M.A.; Hadjisavvas, A.; Hanby, A.; Speirs, V.; Loadman, Paul M.; Linforth, R.; Kyriacou, K.; Sutton, Chris W. | |||||||||
| Pharmacological Inhibition of polysialyltransferase ST8SiaII Modulates Tumour Cell Migration | 2013 | PLoS ONE | 8 | e73366 | Al-Saraireh, Yousef M.J.; Sutherland, Mark H.; Springett, Bradley R.; Freiberger, F.; Ribeiro Morais, Goreti; Loadman, Paul M.; Errington, R.J.; Smith, P.J.; Fukuda, M.; Gerardy-Schahn, R.; Patterson, Laurence H.; Shnyder, Steven D.; Falconer, Robert A. | 10.1371/journal.pone.0073366 | |||||
| FGFR1-induced Epithelial to mesenchymal transition through MAPK/PLCγ/COX-2-mediated mechanisms | 2012 | PLoS ONE | 7 | Tomlinson D.;Baxter E.;Loadman P.;Hull M.;Knowles M. | 1932-6203 | 10.1371/journal.pone.0038972 | |||||
| Synthesis and biological evaluation of colchicine B-ring analogues tethered with halogenated benzyl moieties | 2012 | Journal of Medicinal Chemistry | 55 | 11062 - 11066 | Cosentino L.;Redondo-Horcajo M.;Zhao Y.;Santos A.;Chowdury K.;Vinader V.;Abdallah Q.;Abdel-Rahman H.;Fournier-Dit-Chabert J.;Shnyder S.;Loadman P.;Fang W.;Díaz J.;Barasoain I.;Burns P.;Pors K. | 0022-2623 | 10.1021/jm301151t | ||||
| Synthesis and biological evaluation of colchicine C-ring analogues tethered with aliphatic linkers suitable for prodrug derivatisation | 2012 | Bioorganic and Medicinal Chemistry Letters | 22 | 7693 - 7696 | Fournier-Dit-Chabert J.;Vinader V.;Santos A.;Redondo-Horcajo M.;Dreneau A.;Basak R.;Cosentino L.;Marston G.;Abdel-Rahman H.;Loadman P.;Shnyder S.;Díaz J.;Barasoain I.;Falconer R.;Pors K. | 0960-894X | 10.1016/j.bmcl.2012.09.104 | ||||
| The omega-3 polyunsaturated fatty acid eicosapentaenoic acid inhibits mouse MC-26 colorectal cancer cell liver metastasis via inhibition of PGE |
2012 | British Journal of Pharmacology | 166 | 1724 - 1737 | Hawcroft G.;Volpato M.;Marston G.;Ingram N.;Perry S.;Cockbain A.;Race A.;Munarini A.;Belluzzi A.;Loadman P.;Coletta P.;Hull M. | 0007-1188 | 10.1111/j.1476-5381.2012.01882.x | ||||
| Total synthesis of largazole and analogues: HDAC inhibition, antiproliferative activity and metabolic stability | 2011 | Bioorganic and Medicinal Chemistry | 19 | 3650 - 3658 | Benelkebir H.;Marie S.;Hayden A.;Lyle J.;Loadman P.;Crabb S.;Packham G.;Ganesan A. | 0968-0896 | 10.1016/j.bmc.2011.02.024 | ||||
| Chromatographie analysis of polysialic acid released from neural adhesion molecule presented on glioma cell membranes | 2011 | Kuwait Journal of Science and Engineering | 38 | 107 - 130 | Al-Hasawi N.;Volapato M.;Loadman P. | 1024-8684 | |||||
| Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity | 2011 | Pors, Klaus; Loadman, Paul M.; Shnyder, Steven D.; Sutherland, Mark H.; Sheldrake, Helen M.; Guino, M.; Kiakos, K.; Hartley, J.A.; Searcey, M.; Patterson, Laurence H. | |||||||||
| Anti-colorectal cancer activity of an organometallic osmium arene azopyridine complex | 2011 | MedChemComm | 2 | 666 - 668 | Shnyder S.;Fu Y.;Habtemariam A.;Van Rijt S.;Cooper P.;Loadman P.;Sadler P. | 2040-2503 | 10.1039/c1md00075f | ||||
| Development of a novel tumor-targeted vascular disrupting agent activated by Membrane-type Matrix Metalloproteinases (MT-MMPs) | 2010 | Atkinson, Jennifer M.; Falconer, Robert A.; Edwards, D.R.; Pennington, C.J.; Siller, Catherine S.; Shnyder, Steven D.; Bibby, Michael C.; Patterson, Laurence H.; Loadman, Paul M.; Gill, Jason H. | |||||||||
| Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours. | 2010 | Isambert, N.; Campone, M.; Bourbouloux, E.; Drouin, M.; Major, A.; Yin, W.; Loadman, Paul M.; Capizzi, R.; Grieshaber, C.; Fumoleau, P. | |||||||||
| Effect of eicosapentaenoic acid on E-type prostaglandin synthesis and EP4 receptor signalling in human colorectal cancer cells | 2010 | Hawcroft, G.; Loadman, Paul M.; Belluzzi, A.; Hull, M.A. | |||||||||
| Effect of eicosapentaenoic acid on E-type prostaglandin synthesis and EP4 receptor signaling in human colorectal cancer cells | 2010 | Neoplasia | 12 | 618 - 627 | Hawcroft G.;Loadman P.;Belluzzi A.;Hull M. | 1522-8002 | 10.1593/neo.10388 | ||||
| Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases | 2010 | Cancer Research | 70 | 6902 - 6912 | Atkinson J.;Falconer R.;Edwards D.;Pennington C.;Siller C.;Shnyder S.;Bibby M.;Patterson L.;Loadman P.;Gill J. | 0008-5472 | 10.1158/0008-5472.CAN-10-1440 | ||||
| Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors | 2009 | Hochhauser, D.; Meyer, T.; Spanswick, V.J.; Wu, J.; Clingen, P.H.; Loadman, Paul M.; Cobb, M.; Gumbrell, L.; Begent, R.H.; Hartley, J.A.; Jodrell, D. | |||||||||
| The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study. | 2009 | Steward, W.P.; Middleton, M.; Benghiat, A.; Loadman, Paul M.; Hayward, C.; Walter, S.; Ford, S.; Halbert, G.; Patterson, Laurence H.; Talbot, D. | |||||||||
| In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts | 2009 | Molecular Cancer Therapeutics | 8 | 3266 - 3275 | Williams K.;Albertella M.;Fitzpatrick B.;Loadman P.;Shnyder S.;Chinje E.;Telfer B.;Dunk C.;Harris P.;Stratford I. | 1535-7163 | 10.1158/1535-7163.MCT-09-0396 | ||||
| Detergent addition to trypsin digest and Ion Mobility Separation prior to MS/MS improves peptide yield and Protein Identification for in situ Proteomic Investigation of Frozen and FFPE Adenocarcinoma tissue sections. | 2009 | Djidja, M-C.; Francese, S.; Loadman, Paul M.; Sutton, Chris W.; Scriven, P.; Claude, E.; Snel, M.F.; Franck, J.; Salzet, M.; Clench, M.R. | |||||||||
| Detergent addition to tryptic digests and ion mobility separation prior to MS/MS improves peptide yield and protein identification for in situ proteomic investigation of frozen and formalin-fixed paraffin-embedded adenocarcinoma tissue sections | 2009 | Proteomics | 9 | 2750 - 2763 | Djidja M.;Francese S.;Loadman P.;Sutton C.;Scriven P.;Claude E.;Snel M.;Franck J.;Salzet M.;Clench M. | 1615-9853 | 10.1002/pmic.200800624 | ||||
| In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenograft. | 2009 | Williams, K.J.; Albertella, M.R.; Fitzpatrick, B.; Loadman, Paul M.; Shnyder, Steven D.; Chinje, E.C.; Telfer, B.A.; Dunk, C.R.; Harris, P.A.; Stratford, I.J. | |||||||||
| A mathematical model of doxorubicin penetration through multicellular layers, | 2009 | Evans, C.J.; Phillips, Roger M.; Jones, P.F.; Loadman, Paul M.; Sleeman, B.D.; Twelves, Christopher J.; Smye, S.W. | |||||||||
| Method development for protein profiling in biological tissues by matrix-assisted laser desorption/ionisation mass spectrometry imaging. | 2008 | Djidja, M-C.; Carolan, V.A.; Loadman, Paul M.; Clench, M.R. | |||||||||
| Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: Results of a phase I study | 2008 | Clinical Cancer Research | 14 | 1096 - 1104 | Albertella M.;Loadman P.;Jones P.;Phillips R.;Rampling R.;Burnet N.;Alcock C.;Anthoney A.;Vjaters E.;Dunk C.;Harris P.;Wong A.;Lalani A.;Twelves C. | 1078-0432 | 10.1158/1078-0432.CCR-07-4020 | ||||
| Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase 1 study | 2008 | Albertella, M.R.; Loadman, Paul M.; Jones, P.H.; Phillips, Roger M.; Rampling, R.; Burnet, N.; Alcock, C.; Anthoney, Alan; Vjaters, E.; Dunk, C.R.; Harris, P.A.; Wong, A.; Lalani, A.S.; Twelves, Christopher J. | |||||||||
| Fluorescent 7-Diethylaminocoumarin Pyrrolobenzodiazepine conjugates: Synthesis, DNA-Interaction, Cytotoxicity and Differential Cellular Localization. | 2008 | Wells, G.; Suggitt, Marie; Coffils, M.; Baig, M.A.H.; Howard, P.W.; Loadman, Paul M.; Hartley, J.A.; Jenkins, Terence C.; Thurston, D.E. | |||||||||
| The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study | 2007 | Annals of Oncology | 18 | 1098 - 1103 | Steward W.;Middleton M.;Benghiat A.;Loadman P.;Hayward C.;Waller S.;Ford S.;Halbert G.;Patterson L.;Talbot D. | 0923-7534 | 10.1093/annonc/mdm120 | ||||
| Examination of the distribution of the bioreductive drug AQ4N and its active metabolite AQ4 in solid tumours by imaging matrix-assisted laser desorption/ionisation mass spectrometry | 2007 | Rapid Communications In Mass Spectrometry | 21 | 1271 - 1276 | Atkinson S.;Loadman P.;Sutton C.;Patterson L.;Clench M. | 0951-4198 | 10.1002/rcm.2952 | ||||
| Membrane Type MMPs Show Differential Expression in Non-Small Cell Lung Cancer (NSCLC) Compared to Normal Lung; Correlation of MMP-14 mRNA Expression and Proteolytic Activity. | 2007 | Atkinson, Jennifer M.; Gill, Jason H.; Loadman, Paul M.; Martin, Sandie W.; Pennington, J.; Anikin, V.A.; Mearns, A.J.; Edwards, D.R. | |||||||||
| Membrane type matrix metalloproteinases (MMPs) show differential expression in non-small cell lung cancer (NSCLC) compared to normal lung: Correlation of MMP-14 mRNA expression and proteolytic activity | 2007 | European Journal of Cancer. Part A | 43 | 1764 - 1771 | Atkinson J.;Pennington C.;Martin S.;Anikin V.;Mearns A.;Loadman P.;Edwards D.;Gill J. | 0959-8049 | 10.1016/j.ejca.2007.05.009 | ||||
| Chemical synthesis and biological evaluation of a NAD(P)H:quinone oxidoreductase-1-targeted tripartite quinone drug delivery system | 2007 | Volpato, Milène; Abou-Zeid, N.; Tanner, R.W.; Glassbrook, L.T.; Taylor, James P.; Stratford, I.J.; Loadman, Paul M.; Jaffar, M.; Phillips, Roger M. | |||||||||
| Preclinical pharmacology of the pyrrolobenzodiazepine (PBD) monomer DRH-417 (NSC 709119). | 2007 | Burger, A.M.; Loadman, Paul M.; Thurston, D.E.; Schultz, R.; Fiebig, H.H.; Bibby, Michael C. | |||||||||
| Phase I/II Pilot Study of Intravesical Apaziquone (EO9) for Superficial Bladder Cancer | 2006 | Puri, Rajiv; Palit, V.; Loadman, Paul M.; Flannigan, G. Michael; Shah, T.K.; Choudry, G.A.; Basu, Saurajyoti; Double, John A.; Lenaz, G.; Chawla, S.; Beer, M.; Kalken, C.V.; de Boer, R.; Beijnen, J.H.; Twelves, Christopher J.; Phillips, Roger M. | |||||||||
| Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugates | 2006 | Journal of Medicinal Chemistry | 49 | 5442 - 5461 | Wells G.;Martin C.;Howard P.;Sands Z.;Laughton C.;Tiberghien A.;Woo C.;Masterson L.;Stephenson M.;Hartley J.;Jenkins T.;Shnyder S.;Loadman P.;Waring M.;Thurston D. | 0022-2623 | 10.1021/jm051199z | ||||
| Formation of DNA interstrand cross-links as a marker of Mitomycin C bioreductive activation and chemosensitivity | 2005 | European Journal of Cancer. Part A | 41 | 1331 - 1338 | Volpato M.;Seargent J.;Loadman P.;Phillips R. | 0959-8049 | 10.1016/j.ejca.2005.03.014 | ||||
| Expression of matrix metalloproteinase-10 in human bladder transitional cell carcinoma | 2005 | Urology | 65 | 815 - 820 | Seargent J.;Loadman P.;Martin S.;Naylor B.;Bibby M.;Gill J. | 0090-4295 | 10.1016/j.urology.2004.11.016 | ||||
| Detection of (NAD(P)H:Quinone oxidoreductase-1, EC 1.6.99.2) 609C-->T and 465C-->T polymorphisms in formalin-fixed, paraffin-embedded human tumour tissue using PCR-RFLP. | 2004 | International Journal of Oncology | 24 | 1005 - 1010 | Phillips R.;Basu S.;Brown J.;Flannigan G.;Loadman P.;Martin S.;Naylor B.;Puri R.;Shah T. | 1019-6439 | |||||
| Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent. | 2004 | Wilkinson, Gary P.; Taylor, James P.; Shnyder, Steven D.; Loadman, Paul M.; Cooper, Patricia A.; Howard, P.W.; Thurston, D.E.; Jenkins, Terence C. | |||||||||
| Comparative Preclinical Pharmacokinetic and Metabolic Studies of the Combretastatin Prodrugs Combretastatin A4 Phosphate and A1 Phosphate | 2004 | Kirwan, Ian G.; Loadman, Paul M.; Swaine, David J.; Anthoney, Alan; Pettit, G.R.; Lippert III, J.W.; Shnyder, Steven D.; Cooper, Patricia A.; Bibby, Michael C. | |||||||||
| MMP-10 is overexpressed, proteolytically active and a potential target for therapeutic intervention in human lung carcinomas | 2004 | Gill, Jason H.; Kirwan, Ian G.; Seargent, Jill M.; Martin, Sandie W.; Tijani, S.; Anikin, V.A.; Mearns, A.J.; Bibby, Michael C.; Anthoney, Alan; Loadman, Paul M. | |||||||||
| Immunohistochemical analysis of NAD(P)H:quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours: Relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy | 2004 | Basu, Saurajyoti; Brown, John E.; Flannigan, G. Michael; Gill, Jason H.; Loadman, Paul M.; Naylor, Brian; Scally, Andy J.; Seargent, Jill M.; Shah, Tariq K.; Puri, Rajiv; Phillips, Roger M.; Martin, Sandie W. | |||||||||
| NAD(P)H:Quinone oxidoreductase-1 C609T polymorphism analysis in human superficial bladder cancers: relationship of genotype status to NQO1 phenotype and clinical response to Mitomycin C. | 2004 | Basu, Saurajyoti; Brown, John E.; Flannigan, G. Michael; Gill, Jason H.; Loadman, Paul M.; Martin, Sandie W.; Naylor, Brian; Puri, Rajiv; Scally, Andy J.; Seargent, Jill M.; Shah, Tariq K.; Phillips, Roger M. | |||||||||
| Pharmacological and biological evaluation of a series of substituted 1,4 naphthoquinone bioreductive drugs. | 2004 | Phillips, Roger M.; Loadman, Paul M.; Maitland, Derek J.; Shnyder, Steven D.; Jaffar, M.; Steans, Gillian; Cooper, Patricia A.; Race, Amanda D.; Patterson, A.V.; Stratford, I.J. | |||||||||
| Comet assay and flow cytometry analysis of DNA repair in normal and cancer cells treated with known mutagens with different mechanisms of action. | 2003 | Teratogenesis Carcinogenesis and Mutagenesis | Suppl 2 | 13 - 29 | Suggitt M.;Fearnley J.;Swaine D.;Volpato M.;Phillips R.;Bibby M.;Loadman P.;Anderson D. | 0270-3211 | |||||
| Cytochrome P450 1B1 (CYP1B1) is over-expressed in human colon adeno-carcinomas relative to normal colon: Implications for drug development. | 2003 | Gibson, Paul; Gill, Jason H.; Khan, Parveen A.; Seargent, Jill M.; Martin, Sandie W.; Batman, Philip A.; Griffith, John; Bradley, C.; Double, John A.; Bibby, Michael C.; Loadman, Paul M. | |||||||||
| 5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: Phase I clinical and pharmacokinetic study | 2003 | British Journal of Cancer | 88 | 1160 - 1167 | Rustin G.;Bradley C.;Galbraith S.;Stratford M.;Loadman P.;Waller S.;Bellenger K.;Gumbrell L.;Folkes L.;Halbert G. | 0007-0920 | 10.1038/sj.bjc.6600885 | ||||
| Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9 | 2002 | British Journal of Pharmacology | 137 | 701 - 709 | Loadman P.;Bibby M.;Phillips R. | 0007-1188 | 10.1038/sj.bjp.0704916 | ||||
| A preclinical pharmacokinetic study of the bioreductive drug AQ4N | 2001 | Drug Metabolism and Disposition | 29 | 422 - 426 | Loadman P.;Swaine D.;Bibby M.;Welham K.;Patterson L. | 0090-9556 | |||||
| Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma | 2000 | Anticancer Research | 20 | 229 - 233 | Grosios K.;Loadman P.;Swaine D.;Pettit G.;Bibby M. | 0250-7005 | |||||
| Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: Implications for enzyme-directed bioreductive drug development | 2000 | Cancer Research | 60 | 6384 - 6390 | Phillips R.;Burger A.;Loadman P.;Jarrett C.;Swaine D.;Fiebig H. | 0008-5472 | |||||
| High-performance liquid chromatographic analysis of AQ4N, an alkylaminoanthraquinone N-oxide | 2000 | Journal of Chromatography B: Biomedical Sciences and Applications | 742 | 239 - 245 | Swaine D.;Loadman P.;Bibby M.;Graham M.;Patterson L. | 1387-2273 | 10.1016/S0378-4347(00)00160-2 | ||||
| Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice | 2000 | Biochemical Pharmacology | 59 | 831 - 837 | Loadman P.;Phillips R.;Lim L.;Bibby M. | 0006-2952 | 10.1016/S0006-2952(99)00391-3 | ||||
| Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1 | 1999 | Clinical Cancer Research | 5 | 3682 - 3688 | Loadman P.;Bibby M.;Double J.;Al-Shakhaa W.;Duncan R. | 1078-0432 | |||||
| In vivo metabolism of the antitumor imidazoacridinone C1311 in the mouse and in vitro comparison with humans | 1999 | Drug Metabolism and Disposition | 27 | 240 - 245 | Calabrese C.;Loadman P.;Lim L.;Bibby M.;Double J.;Brown J.;Lamb J. | 0090-9556 | |||||
| Extraction of the synthetic lytic peptide, cecropin B, from biological fluid and analysis using reversed-phase high-performance liquid chromatography | 1995 | Journal of Chromatography - Biomedical Applications | 672 | 225 - 231 | Moore A.;Loadman P.;Devine D.;Bibby M. | 0378-4347 | 10.1016/0378-4347(95)00233-9 |
Reviews
| Title | Year | Publication name | Journal | Volume | Pages | Authors | Editors | ISSN | Publisher | DOI | Location |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance | 2019 | Critical Reviews in Oncology/Hematology | 141 | 153 - 162 | Jove M.;Spencer J.;Clench M.;Loadman P.;Twelves C. | 1040-8428 | 10.1016/j.critrevonc.2019.06.008 | ||||
| Proteases in cancer drug delivery | 2016 | Advanced Drug Delivery Reviews | 97 | 144 - 155 | Vandooren J.;Opdenakker G.;Loadman P.;Edwards D. | 0169-409X | 10.1016/j.addr.2015.12.020 | ||||
| Use of matrix-assisted laser desorption/ionisation mass spectrometry in cancer research | 2011 | Journal of Pharmacological and Toxicological Methods | 64 | 197 - 206 | Bateson H.;Saleem S.;Loadman P.;Sutton C. | 1056-8719 | 10.1016/j.vascn.2011.04.003 | ||||
| Separation methods for anthraquinone related anti-cancer drugs | 2001 | Journal of Chromatography B: Biomedical Sciences and Applications | 764 | 193 - 206 | Loadman P.;Calabrese C. | 1387-2273 | 10.1016/S0378-4347(01)00281-X | ||||
| Current advances in the inhibition of the auto-regulatory interaction between the p53 tumour suppressor protein and MDM2 protein | 2001 | Expert Opinion on Therapeutic Patents | 11 | 1825 - 1835 | Picksley S.;Dart D.;Mansoor M.;Loadman P. | 1354-3776 | 10.1517/13543776.11.12.1825 | ||||
| Is tumour-expressed aminopeptidase N (APN/CD13) structurally and functionally unique? | 2021 | Biochimica et Biophysica Acta - Reviews on Cancer | 1876 | Barnieh F.M.;Loadman P.M.;Falconer R.A. | 0304-419X | 10.1016/j.bbcan.2021.188641 | |||||
| Progress towards a clinically-successful ATR inhibitor for cancer therapy | 2021 | Current Research in Pharmacology and Drug Discovery | 2 | Barnieh F.M.;Loadman P.M.;Falconer R.A. | 2590-2571 | 10.1016/j.crphar.2021.100017 |